ŷ��Ʒ Feature Channel: Immunology

Cleveland Clinic Researchers Discover New Bacterium that Causes Gut Immunodeficiency

Cleveland Clinic — Thu, 26 Sep 2024 14:00:00 EST

Cleveland Clinic researchers have discovered a new bacterium that weakens the immune system in the gut, potentially contributing to certain inflammatory and infectious gut diseases. The team identified the bacterium, Tomasiella immunophila (T. immunophila), which plays a key role in breaking down a crucial immune component of the gut's multi-faceted protective immune barrier. Identifying this bacterium is the first step to developing new treatments for a variety of inflammatory and infectious gut diseases.

Why Flu Shots Are Important for Kids

Children's Hospital Los Angeles — Thu, 26 Sep 2024 13:05:27 EST

If it's autumn, then it must be influenza season, which means it's time to consider flu shots for your family.The U.S. Centers for Disease Control and Prevention (CDC), American Academy of Pediatrics, and Infectious Diseases Society of America recommend that everyone approved to receive a flu shot get one--including children ages 6 months and older.

Estrogen: Women's Secret Recipe To Longevity

Hevolution Foundation — Tue, 24 Sep 2024 14:05:12 EST

Longevity research is focussed on extending our time in good health, with the goal of increasing healthspan--the years spent in optimal well-being--rather than simply adding more years to life.

Naked Mole-Rat Has Become the First Mammalian to Have Waived Infection-Resistant Proteins

Scientific Project Lomonosov — Tue, 24 Sep 2024 07:05:12 EST

Scientists have found that the naked mole-rat -- an underground rodent that lives up to 40 years -- has lost a number of CD1 functional genes. The CD1 gene family in mammals is responsible for protein synthesis that protects the body against infectious diseases. The findings indicate that the naked mole-rat's immune system has significantly realigned and is using other -- CD1-independent -- molecular mechanisms. The results of the studies, supported by the Grants of Presidential program of the Russian Science Fund (RSF), were published in the Biology Direct magazine.

SLU Researchers Identify Sex-Based Differences in Immune Responses Against Tumors

Saint Louis University — Fri, 20 Sep 2024 10:05:10 EST

Researchers at Saint Louis University School of Medicine investigated differences in T-cell responses between male and female patients with lung cancer that may help direct future treatments. T-cell responses are part of the adaptive immune system, which is part of the body's "smart system" that monitors for threats and fights them with customized defenses.

What To Know About Vaccines As We Enter the Winter Season

George Washington University — Thu, 19 Sep 2024 10:05:43 EST

Ut Southwestern Biochemist Zhijian 'James' Chen, Ph.D., Earns Prestigious Lasker Award

UT Southwestern Medical Center — Thu, 19 Sep 2024 09:05:57 EST

Zhijian "James" Chen, Ph.D., Professor of Molecular Biology and Director of the Center for Inflammation Research at UT Southwestern Medical Center, has been awarded the Albert Lasker Basic Medical Research Award for his discovery of the cGAS enzyme.

UChicago Medicine Patient First in the World to Receive Ulcerative Colitis Drug Since FDA Approval

University of Chicago Medical Center — Wed, 18 Sep 2024 09:05:38 EST

A University of Chicago Medicine patient became the first in the world to receive the drug guselkumab (Tremfya) since its Sept. 11 approval by the FDA for treating moderate to severe ulcerative colitis.

Scientists at The Wistar Institute Clone Several New Anti-Interferon Antibodies - Developing Future Therapeutic Candidates with Broad Application Potential

Wistar Institute — Tue, 17 Sep 2024 14:05:21 EST

Wistar Institute scientists have successfully isolated and cloned fully human antibodies that can block specific Type-I interferon molecules in vitro; their discovery has an array of potential clinical & research applications, enabling scientists with a new way to investigate the role of specific Type-I interferons in a variety of diseases.

Large-Scale Study Will Seek to Unearth Causes of Persistent Symptoms of Lyme Disease

Tufts University — Tue, 17 Sep 2024 10:05:40 EST

Tufts University researchers have received a $20.7 million grant to lead the largest NIH-funded prospective study of patients with chronic Lyme disease to date, following patients from their earliest diagnosis to better identify why some people go on to develop debilitating symptoms later on.

T cells may offer some protection in an H5N1 'spillover' scenario

La Jolla Institute for Immunology — Mon, 16 Sep 2024 13:05:34 EST

The LJI team uncovered important similarities between H5N1 and these common viruses, which allowed them to predict that many people already have "cross-reactive" T cells that are ready to target H5N1--should it ever mutate to cause widespread disease in humans.

Testing a Revolutionary Treatment Against Progressive Multiple Sclerosis

Rutgers University-New Brunswick — Mon, 16 Sep 2024 12:05:04 EST

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an engineered immune cell therapy can halt the progression of the autoimmune disease.

Montefiore Einstein Comprehensive Cancer Center Establishes New Immunotherapy Institute

Montefiore Einstein Comprehensive Cancer Center — Mon, 16 Sep 2024 09:05:13 EST

The National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) has announced the new Marilyn and Stanley M. Katz Institute for Immunotherapy for Cancer and Inflammatory Disorders. Xingxing Zang, Ph.D., an international leader in developing novel immunotherapies, has been named its inaugural director.

MS Patients with Chronic Brain Lesions Decline Faster

American Neurological Association (ANA) — Mon, 16 Sep 2024 08:00:05 EST

Starting patients with multiple sclerosis (MS) on aggressive treatment earlier may help prevent the development of paramagnetic rim lesions (PRL), areas of chronic brain inflammation that are linked to faster decline due to the disease, suggests new research presented at the 149th Annual Meeting of the American Neurological Association (ANA). People with MS who have PRLs tend to have greater brain atrophy and disability. Treatment for MS includes low-, moderate- or high-efficacy disease-modifying therapies (DMTs), such as monoclonal antibodies, immunomodulators and immunosuppressants. While high-efficacy DMTs have more side effects, previous research suggests they may help prevent PRLs from forming (unlike low- or moderate-efficacy DMTs), potentially outweighing the downsides. No currently available DMT has been shown to reduce existing PRLs.

Albert Einstein College of Medicine Receives Major Federal Grant to Help Lead National Effort for Pandemic Preparedness

Albert Einstein College of Medicine — Fri, 13 Sep 2024 15:30:43 EST

Albert Einstein College of Medicine has received a five-year, $14 million per year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to participate in a broad national effort to develop "plug-and-play" vaccines and antibody-based therapies against a wide range of emerging viruses. The grant is part of NIAID's new Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network, which was announced earlier today.

Your Best Bet for Avoiding Illness from Flu and COVID-19? Getting Vaccinated.

Rutgers University-New Brunswick — Fri, 13 Sep 2024 09:05:32 EST

An infectious disease expert at Rutgers Health explains the importance of getting crucial shots this fall

Do Genetic "Parasites" Help the Immune System Develop and Function?

Universite de Montreal — Thu, 12 Sep 2024 16:05:59 EST

A study by UdeM professor Claude Perreault's team at IRIC proposes three potential functions for so-called parasite DNA sequences in T cell development.

LJI Selected as Member of ARPA-H Investor Catalyst Hub Spoke Network

La Jolla Institute for Immunology — Wed, 11 Sep 2024 12:05:47 EST

La Jolla Institute for Immunology (LJI) has been selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).

TORL BioTherapeutics Announces Appointment of Howard A. "Skip" Burris III, MD, FACP, FASCO as Board Member

TORL Biotherapeutics LLC — Tue, 10 Sep 2024 16:05:20 EST

TORL BioTherapeutics, LLC (TORL), a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, today announced the appointment of Howard A. "Skip" Burris III, MD, FACP, FASCO as Board Member.

MD Anderson Research Highlights Special Edition: ESMO 2024

University of Texas MD Anderson Cancer Center — Tue, 10 Sep 2024 10:00:01 EST

The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.

ŷ����Ʒ Feature Channel: Immunology